Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: synchro who wrote (2606)	5/4/1999 12:16:00 AM
From: RCMac	Read Replies (1) of 10280

>>Its R&D is funded, as of now and the foreseeable future, by investor charity.<< ??? Well, actually, since it sold $300 million in convertible debentures in December, SEPR has a half billion in cash on its balance sheet, enough to pay for a lot of R&D at its current rate of something like $100 million a year (not to mention the several hundred million being spent each year on development of SEPR's ICEs by Schering, J&J, Lilly, etc.). IMO, SEPR is worth a lot more than >>one sixteenth of Amgen's market value<< SEPR's pipeline is superior, and the risk of FDA non-approval of SEPR's ICEs is much smaller than for AMGN's pipeline candidates. --RCM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next